Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare.

Asahi Intecc Co., Ltd. engages in the development, manufacture, and sale of medical and industrial equipment products. It operates through the Medical and Device segments. The Medical segment deals with the development, manufacture, and sale of self-branded and original equipment manufacturer products of medical equipment. The Device segment manufactures and sells parts for medical and industrial equipment. The company was founded on July 8, 1976 and is headquartered in Nagoya, Japan.

Bard Access Systems, Inc. develops, manufactures and distributes medical devices. It makes vascular access products as dialysis & pheresis catheters, implanted ports, ultrasound systems and surgical accessories. The company was founded in 1947 and is headquartered in Salt Lake City, UT.

B. Braun Melsungen AG manufactures and distributes pharmaceutical products and medical equipment. Its products are used in the treatment of degenerative spinal diseases, diabetes management, nutritional therapy, extracorporeal blood treatment, laparoscopy, neurosurgery, wound management, and urology. The company was founded on June 23, 1839 and is headquartered in Melsungen, Germany.

Part of Becton, Dickinson & Co., Becton, Dickinson & Co. Ltd. is an Irish company located in Dublin. The firm manufactures and supplies medical devices.

ECP Entwicklungsgesellschaft mbH, part of Johnson & Johnson, is a company headquartered in Berlin, Germany, that manufactures medical devices. It was acquired by ABIOMED, Inc., now part of Johnson & Johnson from Syscore GmbH on July 01, 2014 for $28.02 million.

Hollister, Inc. develops, manufactures and markets healthcare products and services. Its products include Ostomy, continence, wound, skin and critical care products. The company was founded by John Dickinson Schneider in 1921 and is headquartered in Libertyville, IL.

Avent, Inc., a subsidiary of Avanos Medical, Inc., is an American company that develops and manufactures pharmaceuticals.

Anuncia Medical is an early-stage commercial, patient-centric MedTech company with the US cleared and EU-approved, clinically validated, noninvasive, therapeutic device solutions and a robust product pipeline to disrupt the Cerebrospinal Fluid (CSF) Management space. We uniquely address the largest unmet need in CSF Management; the high rate of ventriculoperitoneal (VP) shunt occlusion. VP shunts fail at a rate of 50% within 2 years and 80% within 5 years, contributing to repeat revision brain surgeries (each costing upwards of $40,000). Conceptualized in 2014 in collaboration with Boston Children’s Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia’s patented portfolio of technologies provide peace-of-mind through innovation to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders and their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions. Anuncia’s core platform has an elegant mechanism of action using a simple finger depression of a soft silicone dome located under the patient’s scalp to produce a noninvasive, retrograde flush of the patient’s own CSF to restore flow through an occluded catheter and prevent emergency surgery. ReFlow’s initial clinical evidence of flow restoration and reduction of symptoms via acute intervention flushing with follow-up up to 3 years, led neurosurgeons to evaluate ReFlow for prophylactic occlusion prevention in their high-risk patients. Ground-breaking clinical data, now out up to 2 years with 100% success, suggest ReFlow is safe for at-home, prophylactic flushing by patients or caregivers to extend shunt life and eliminate revision brain surgery. Supported by these encouraging results, the U.S. Food and Drug Administration (FDA) granted ReFlow Breakthrough Device status in 2021, making it eligible for regulatory and reimbursement advantages. With existing profitable reimbursement, Anuncia plans to launch its next-generation ReFlow Mini product line in Q2 2022 and continue clinical studies to support market adoption and premium reimbursement. With Breakthrough status and strong health economic advantages to improve hospital quality metrics and support New Technology Add-on Payment (NTAP) for rapid market adoption and premium pricing; Anuncia is positioned to be the leader in CSF management and help patients live fuller lives. ReFlow’s unique ability to improve patient access to noninvasive lifesaving therapy at home or in the clinic and to improve clinical outcomes and quality of life, and reduce healthcare costs, earned it an Honorable Mention in the Fast Company 2021 World-Changing Ideas Awards and landed it on MDDI’s The Ultimate List of Private Companies to Watch.

ICU Medical connects patients and caregivers through safe, life-saving, life-enhancing medical devices. They provide clinicians around the world with innovative and cost-effective patient care solutions for unmet clinical needs. Their products help clinicians improve patient outcomes by minimizing bacterial ingress that can cause bloodstream infections and preventing exposure to infectious diseases or hazardous drugs. Our diverse product line includes needlefree vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, advanced sensor catheters, needlefree closed blood sampling systems, and innovative hemodynamic monitoring systems. These clinically-proven innovations are the result of a unique company culture, supported by visionary leaders and resourceful minds, united by the common desire to redefine the limits of patient and healthcare worker safety.

Magic Leap is a proprietary wearable technology that enables users to interact with digital devices in a completely visually cinematic way. Magic Leap is an Augmented Reality US-based startup that is innovating in the AR space to create new hardware and software that will give its users a never-before-seen AR experience and redefine how they access screens and visualize data. The headset combines a user's inherent visual ability with mobile computing – giving visual output equivalent to real-world experience but powered by mobile tech. Using their Dynamic Digitized Lightfield Signal, they generate images indistinguishable from real objects and place those images seamlessly into the real world.

InnovHeart Srl is a holding company, which engages in the development of transcatheter mitral valve replacement (TMVR) systems for the treatment of patients with mitral valve disease. It also develops Saturn Prosthesis, Transapical, and Transeptal systems that are designed to be consistent with the anatomy of the mitral valve. The company was founded by Giovanni Righini and is headquartered in Milan, Italy.

Fresenius Kabi Deutschland GmbH, part of Fresenius SE & Co. KGaA, is a company headquartered in Bad Homburg vor der Hohe, Germany, that manufactures drugs in pharmaceutical preparations for human and veterinary use. The firm was founded in 1999. Steffen Roser, Christoph Funke and Tanja Greve are the current co-CEOs of the company.

Retractable Technologies offers education and the development of safe and reliable medical devices. They provide a diameter tube adapter, the blood collection tube holder, allergy tray, the iv safety catheter, and the patient-safe syringes.

AccuMedical is a full-line product company in the field of neurological intervention, headquartered in Beijing with an R&D center located in California. It develops and produces medical device products for the treatment of aneurysms, preventing, and treating bleeding diseases caused by the rupture of vascular aneurysms.

Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a company headquartered in Konstanz, Germany, that manufactures pharmaceutical products. The firm was founded in 1873. Wolfgang Eck, Uwe Hoffmeister and Roland Kurney are the current co-CEOs of the company.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).